Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$109 Mln
P/E Ratio
17.56
P/B Ratio
19.97
Industry P/E
--
Debt to Equity
0
ROE
0.38 %
ROCE
--
Div. Yield
0 %
Book Value
0.4
EPS
--
CFO
$-10.04 Mln
EBITDA
$-33.94 Mln
Net Profit
$-45.65 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Champions Oncology (CSBR)
| -7.82 | -19.39 | -31.90 | 57.06 | -0.04 | -0.13 | 0.93 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Champions Oncology (CSBR)
| 51.97 | 24.61 | -46.05 | -22.52 | 29.53 | 6.66 | 100.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.68 | 4.62 | -- | -- | |
| 2.76 | 88.86 | -- | -62.31 |
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized... cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Read more
CEO & Director
Dr. Ronnie Morris M.D.
CEO & Director
Dr. Ronnie Morris M.D.
Headquarters
Hackensack, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Champions Oncology Inc (CSBR) stood at $ 50 Mln as on 31-Jan-25
The share price of Champions Oncology Inc (CSBR) is $7.90 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Champions Oncology Inc (CSBR) has given a return of -0.04% in the last 3 years.
Champions Oncology Inc (CSBR) has a market capitalisation of $ 109 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Champions Oncology Inc (CSBR) is 19.97 times as on 25-Apr-2025, a 772% premium to its peers’ median range of 2.29 times.
The P/E ratio of Champions Oncology Inc (CSBR) is 17.56 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Champions Oncology Inc (CSBR) and enter the required number of quantities and click on buy to purchase the shares of Champions Oncology Inc (CSBR).
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
The CEO & director of Dr. Ronnie Morris M.D.. is Champions Oncology Inc (CSBR), and CFO & Sr. VP is Dr. Ronnie Morris M.D..
There is no promoter pledging in Champions Oncology Inc (CSBR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
9
|
|
|
0
|
|
|
9
|
|
|
0
|
| Champions Oncology Inc. (CSBR) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
11.48
|
|
Net Margin(%)
|
10.97
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Champions Oncology Inc (CSBR) was $0 Mln.
$0.29
(
